Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report

RATIONALE: Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Hsiu, Liu, Feng-Cheng, Hsu, Chang-Hung, Chian, Chih-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502156/
https://www.ncbi.nlm.nih.gov/pubmed/28682883
http://dx.doi.org/10.1097/MD.0000000000007350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502156/
https://www.ncbi.nlm.nih.gov/pubmed/28682883
http://dx.doi.org/10.1097/MD.0000000000007350

Ejemplares similares